Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Korro Bio (NASDAQ: KRRO), a clinical-stage biopharmaceutical company developing RNA-editing genetic medicines, has announced key leadership appointments. Loïc Vincent, Ph.D. joins as Chief Scientific Officer, bringing over 20 years of drug discovery experience and a track record of advancing more than 20 drugs into clinical development.
The company also appointed GaoZhong Zhu, Ph.D. as Senior Vice President of CMC & Technical Operations, leveraging his 25+ years of pharmaceutical development experience. Additionally, Oliver Dolan was promoted to Principal Accounting Officer.
Korro is currently conducting the Phase 1/2a REWRITE clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency. The company's RNA-editing platform aims to develop treatments for both rare and highly prevalent diseases.
Korro Bio (NASDAQ: KRRO), un'azienda biofarmaceutica in fase clinica che sviluppa farmaci genetici tramite editing dell'RNA, ha annunciato importanti nomine nella leadership. Loïc Vincent, Ph.D. entra come Chief Scientific Officer, portando oltre 20 anni di esperienza nella scoperta di farmaci e un bilancio di oltre 20 farmaci avanzati nello sviluppo clinico.
L'azienda ha anche nominato GaoZhong Zhu, Ph.D. come Vicepresidente Senior delle Operazioni Tecniche e CMC, sfruttando oltre 25 anni di esperienza nello sviluppo farmaceutico. Inoltre, Oliver Dolan è stato promosso a Principal Accounting Officer.
Korro sta attualmente conducendo lo studio clinico di Fase 1/2a REWRITE di KRRO-110 per la Deficienza di Alfa-1 Antitripsina. La piattaforma di editing dell'RNA dell'azienda mira a sviluppare trattamenti per malattie sia rare che altamente prevalenti.
Korro Bio (NASDAQ: KRRO), una empresa biofarmacéutica en etapa clínica que desarrolla medicamentos genéticos mediante edición de ARN, ha anunciado nombramientos clave en su liderazgo. Loïc Vincent, Ph.D. se une como Director Científico, aportando más de 20 años de experiencia en el descubrimiento de fármacos y un historial de más de 20 medicamentos avanzados al desarrollo clínico.
La empresa también nombró a GaoZhong Zhu, Ph.D. como Vicepresidente Senior de CMC y Operaciones Técnicas, aprovechando sus más de 25 años de experiencia en desarrollo farmacéutico. Además, Oliver Dolan fue ascendido a Oficial Principal de Contabilidad.
Korro está llevando a cabo actualmente el estudio clínico de Fase 1/2a REWRITE de KRRO-110 para la Deficiencia de Alfa-1 Antitripsina. La plataforma de edición de ARN de la empresa tiene como objetivo desarrollar tratamientos tanto para enfermedades raras como para aquellas altamente prevalentes.
Korro Bio (NASDAQ: KRRO), RNA 편집 유전자 의약품을 개발하는 임상 단계의 생물 제약 회사가 주요 리더십 임명을 발표했습니다. Loïc Vincent, Ph.D.가 최고 과학 책임자로 합류하며, 20년 이상의 약물 발견 경험과 20개 이상의 약물을 임상 개발로 발전시킨 경력을 가지고 있습니다.
회사에서는 GaoZhong Zhu, Ph.D.를 CMC 및 기술 운영의 선임 부사장으로 임명하였으며, 25년 이상의 제약 개발 경험을 활용하고 있습니다. 또한 Oliver Dolan은 주요 회계 책임자로 승진하였습니다.
Korro는 현재 알파-1 항트립신 결핍증을 위한 KRRO-110의 1/2a상 REWRITE 임상 연구를 진행하고 있습니다. 회사의 RNA 편집 플랫폼은 희귀 질환과 널리 퍼진 질환 모두에 대한 치료법을 개발하는 것을 목표로 하고 있습니다.
Korro Bio (NASDAQ: KRRO), une entreprise biopharmaceutique en phase clinique développant des médicaments génétiques par édition de l'ARN, a annoncé des nominations clés au sein de sa direction. Loïc Vincent, Ph.D. rejoint l'entreprise en tant que directeur scientifique, apportant plus de 20 ans d'expérience dans la découverte de médicaments et un palmarès de plus de 20 médicaments avancés vers le développement clinique.
L'entreprise a également nommé GaoZhong Zhu, Ph.D. au poste de vice-président senior des opérations techniques et CMC, tirant parti de ses plus de 25 ans d'expérience en développement pharmaceutique. De plus, Oliver Dolan a été promu au poste de directeur comptable principal.
Korro mène actuellement l'étude clinique de phase 1/2a REWRITE de KRRO-110 pour le déficit en alpha-1 antitrypsine. La plateforme d'édition de l'ARN de l'entreprise vise à développer des traitements pour des maladies à la fois rares et très répandues.
Korro Bio (NASDAQ: KRRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das RNA-bearbeitende genetische Medikamente entwickelt, hat wichtige Führungspositionen neu besetzt. Loïc Vincent, Ph.D. tritt als Chief Scientific Officer bei und bringt über 20 Jahre Erfahrung in der Arzneimittelentdeckung sowie eine Erfolgsbilanz von mehr als 20 in die klinische Entwicklung überführten Medikamenten mit.
Das Unternehmen ernannte auch GaoZhong Zhu, Ph.D. zum Senior Vice President für CMC und technische Operationen, wobei er auf über 25 Jahre Erfahrung in der pharmazeutischen Entwicklung zurückgreifen kann. Darüber hinaus wurde Oliver Dolan zum Principal Accounting Officer befördert.
Korro führt derzeit die klinische Studie der Phase 1/2a REWRITE für KRRO-110 zur Alpha-1-Antitrypsin-Mangel durch. Die RNA-Bearbeitungsplattform des Unternehmens zielt darauf ab, Behandlungen sowohl für seltene als auch für weit verbreitete Krankheiten zu entwickeln.
- Strengthened leadership team with experienced CSO who led development of 20+ drugs
- Ongoing Phase 1/2a clinical trial for lead candidate KRRO-110
- Added expertise in CMC and technical operations with new SVP appointment
- None.
Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company’s Chief Scientific Officer.
“We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy,” said Ram Aiyar, Ph.D., CEO and President of Korro. “He joins us at an important time as we advance multiple candidates in our pipeline, including KRRO-110, which is currently being evaluated in the Phase 1/2a REWRITE clinical study for Alpha-1 Antitrypsin Deficiency.”
“Korro’s unique RNA-editing platform has the potential to bring transformative genetic medicines to patients with rare and highly prevalent diseases and provide hope where there is significant unmet need,” said Dr. Vincent. “I look forward to supporting the mission at Korro and joining its talented management team.”
Dr. Vincent joins Korro with more than 20 years in drug discovery and translational research across academia, biotech and the pharmaceutical industry. Throughout his career, Dr. Vincent led teams that advanced more than 20 drugs into clinical development based on various therapeutic modalities including small molecules, biologics, viral platforms and cell therapies.
Prior to joining Korro, Dr. Vincent served as Chief Scientific Officer at Affini-T Therapeutics leading efforts to advance next-generation therapies. Previously, he was Head of the Oncology Drug Discovery Unit and Immunology Unit at Takeda. Before that, Dr. Vincent led Oncology Drug Discovery Pharmacology, Immunotherapy and Oncology External Innovation teams at Sanofi, and earlier in his career, he headed Pharmacology and Oncology programs at Endotis Pharma. Dr. Vincent currently serves on the Scientific Advisory Boards of bit.bio and General Inception, and is a Director on the Board of Alaya.bio. Dr. Vincent obtained his Ph.D. in pharmacology from the University of Rouen, France, and completed his postdoctoral fellowship in oncology at the Weill Medical College of Cornell University, New York.
Additionally, Korro announced two key leadership appointments:
- GaoZhong Zhu, Ph.D. joined Korro as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations. With more than 25 years of industrial experience in developing and implementing CMC strategies for various types of pharmaceuticals, Dr. Zhu has a proven track record of bringing new products from conception to commercialization further reinforcing Korro’s commitment to advancing its innovative pipeline. Prior to joining Korro, he held key pharmaceutical development and manufacturing positions at Eagle Pharmaceuticals and Corvidia Therapeutics as well as positions of increasing responsibility at Shire and Biogen. Dr. Zhu is an inventor of multiple patents in drug delivery and formulations. He holds a Ph.D. in Pharmaceutics from The Ohio State University and Bachelor of Science/Master of Science degrees in Chemistry from Peking University.
- Oliver Dolan was promoted to Principal Accounting Officer. He has served as Korro’s Senior Vice President of Finance since January 2024. Prior to joining Korro, Mr. Dolan held key finance roles with Unity Biotechnology, Haven Healthcare, and Compass Therapeutics. Mr. Dolan holds an MBA from MIT Sloan School of Management and a Bachelor of Commerce degree from the University College Dublin and is licensed as a Certified Public Accountant.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro regarding the future including, without limitation, express or implied statements regarding: the timing of data readouts and completion of the Phase 1/2a REWRITE clinical trial; among others. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including risks of conducting a clinical study; risks associated with regulatory oversight of clinical studies, enrollment risks and risks of expanding to other jurisdictions along with other risks inherent in biopharmaceutical development; risks associated with pre-clinical studies and clinical studies; and other risks associated with obtaining regulatory approvals and protecting intellectual property; as well as risks associated with general economic conditions (including recent geopolitical uncertainty and potential supply chain disruptions due to changes in economic policy); and other risks and uncertainties indicated from time to time in Korro’s filings with the SEC, including Part I Item 1A. “Risk Factors” in Korro’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, as such may be amended or supplemented by its other filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Korro does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Korro.
Korro Bio Contact Information
Investor & Media Contact
Tim Palmer
IR@korrobio.com
FAQ
What is the current clinical trial status of Korro Bio's (KRRO) lead candidate?
Who is the new Chief Scientific Officer at Korro Bio (KRRO) and what is their experience?
What therapeutic areas does Korro Bio (KRRO) focus on with its RNA-editing platform?
What recent leadership changes were announced at Korro Bio (KRRO) in April 2025?
